Results 111 to 120 of about 17,802 (177)

Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from <i>in vitro</i> experiments, animal models and human studies. [PDF]

Front Immunol
Ricigliano VAG.
europepmc   +1 more source

Clinical Impact of Fingolimod-Associated Lymphopenia in Multiple Sclerosis: A Real-World Cohort Study. [PDF]

Medicina (Kaunas)
Yeniçeri M, Şenoymak MC, Baş S, Çoban HH, Gürbüz Yeniçeri A, Demir S, Tanoglu A.   +6 more
europepmc   +1 more source

Chronic HPV associated lesions associated with Fingolimod use

, 2018
Background: Fingolimod is a an effective immunosuppressive therapy used to reduce relapse rates in relapsing remitting MS. Fingolimod is a sphingosine 1-phosphate (S1-P) analogue and has antagonistic effects on S1-P receptors causing in S1-P receptor ...
Kermode, A.G., Triplett, J.D.
core  

Cardiac arrhythmias associated with S1PRMs: a pharmacovigilance study based on real-world data. [PDF]

Front Pharmacol
Wang S, Xie L, Ma P.
europepmc   +1 more source

Errate: Nasal Mucociliary Clearance and Its Relationship With Disease Severity in Patients With Multiple Sclerosis. [PDF]

Med Sci Monit
Baydar C, Yalınkılıç A, Çetin YS.
europepmc   +1 more source

Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells. [PDF]

PLoS Pathog
Moraga E, Climent N, Sánchez-Molina A, Vicens-Artés S, Maleno MJ, Valero López G, Galera Peñaranda C, Ambrosioni J, Miró JM, Mallolas J, Albendín-Iglesias H, Alcamí J, Sánchez-Palomino S.   +12 more
europepmc   +1 more source

The multiple sclerosis drug fingolimod induces pore-like membrane defects, contributing to its antimicrobial activity. [PDF]

J Biol Chem
Syam A, Rees B, Cuervo S, Xue F, Sodt AJ, Nestorovich EM, Rostovtseva TK, Bezrukov SM, Choy JS.   +8 more
europepmc   +1 more source

Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study. [PDF]

J Neurol
Bove R, Langdon D, Maciejowski M, Jasińska E, Dufek M, Abeyewickreme A, Rauh A, Fu H, Khan IA, Böhringer M, Eichau SM, Derfuss T.   +11 more
europepmc   +1 more source

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis. [PDF]

Brain
Maleska Maceski A, Benkert P, Einsiedler M, Schaedelin S, Oechtering J, Melie-Garcia L, Cagol A, Galbusera R, Galli E, Müller J, Finkener S, Lalive PH, Uginet M, Müller S, Pot C, Mathias A, Du Pasquier R, Hoepner R, Chan A, Disanto G, Zecca C, D'Souza M, Hemkens LG, Yaldizli Ö, Derfuss T, Roth P, Gobbi C, Brassat D, Tackenberg B, Pedotti R, Raposo C, Oksenberg J, Green AJ, Wiendl H, Berger K, Hermesdorf M, Piehl F, Conen D, Kappos L, Khalil M, Granziera C, Abdelhak A, Leppert D, Willemse EAJ, Kuhle J, Swiss Multiple Sclerosis Cohort (SMSC) .   +45 more
europepmc   +1 more source

Repurposing Fingolimod as an Antibacterial and Antibiofilm Agent against Carbapenem-Resistant <i>Acinetobacter baumannii</i>. [PDF]

ACS Omega
Jin HW, Bae JH, Youn HS, Eom YB.
europepmc   +1 more source